Malaria is the most widespread infectious parasitic disease around the world ([@B27]). The burden of emerging parasites resistant to artemisinin combination therapies threatens global efforts to control malaria, making the need for new antimalarial drugs urgent ([@B18]). However, the molecular mechanisms of artemisinin resistance are unknown ([@B20]). Among the numerous genes involved in artemisinin resistance, PfATP6, a sarco/endoplasmic reticulum Ca^2+^-ATPase (SERCA) homologue expressed in *Plasmodium falciparum*, has been suggested as a possible target of artemisinin ([@B26], [@B7]).

Overcoming the major difficulties in the development of new antimalarial candidates relies on efficient candidate synthesis and a better understanding of the mechanism of action of defined targets ([@B16]). In this context, our research group recently demonstrated the in vitro antiplasmodial activity of oxidised/epoxidised *ent*-kaurane diterpene derivatives obtained from the naturally occurring ent-kaurenes of *Wedelia paludosa* DC ([@B2]). Due to the selective antimalarial activity exhibited by these compounds and knowing that diterpenes induce calcium overload in myocytes ([@B23]) we investigated the interaction between the *ent*-kaurane diterpenes and PfATP6 ([@B10]). SERCA are crucial for calcium signalling in malarial parasites ([@B9], [@B12]). Calcium signalling is associated with the regulation of many processes during the parasite life cycle, including modulation of kinase activity and synchronisation of the intraerythrocytic cycle ([@B1]). Molecular mechanisms that maintain parasite calcium homeostasis are controlled by proteins such as PfATP6 ([@B11]). Any alteration to calcium homeostasis, triggered by the inhibition of PfATP6, could promote an increase in cytoplasmic calcium, leading to the activation of the metacaspase PfMCA-1 ([@B17]). This mode of action could provide a new strategy to design new pro-apoptotic antimalarial drugs.

Thus, the aim of this study was to construct the PfATP6 enzyme model and perform a rigid and flexible molecular docking analysis of synthetic and semisynthetic diterpenes derived from *W. paludosa* DC.

Initially, the primary sequence of the PfATP6 was obtained from the *Plasmodium* genomics Resource (plasmodb.org/plasmo/). Subsequently, a three-dimensional model was built following a comparative modelling approach. The model was constructed using SwissPDB Viewer 3.7 following a standard protocol as previously described ([@B5]): (i) load the primary sequence of PfATP6, (ii) search for templates against Protein Data Bank ([@B3]) and (iii) perform structural alignment and submit it to the Swiss Model Server. In this process, the atomic coordinates of thapsigargin (TG), the natural SERCA inhibitor, were transferred from 1IWO ([@B24]) to build the model. The resultant model was refined by AMBER ([@B6] using the *ff03*force field ([@B21]. First, the parameters of TG were determined using the antechamber program and AM1-BCC charges, in which the atom types were assigned by the general amber force field (gaff). Second, the complex enzyme (PfATP6-TG) was prepared by the Leap program, constructing the topological and coordinate files. The complex enzyme was minimised in vacuum followed by application of the generalised Born implicit solvent model with 5,000 steep descent steps and 5,000 conjugate gradient steps in each environment ([@B14]. Subsequently, 59 structures were constructed and refined by the semiempirical PM6 ([@B22] method ([@B4] implemented in Gaussian 09 W software ([@B8]. The ligands (Supplementary [Fig. 1](#f01){ref-type="fig"}) and molecular targets were prepared by MGL Tools software using a standard protocol ([@B25]. A grid box was constructed around the ligand and was sufficiently large to cover the entire binding site to limit the docking space (Supplementary [Table](#t1){ref-type="table"} I). In sequence, TG was re-docked into the built model to evaluate the docking methodology (Supplementary [Fig. 2](#f02){ref-type="fig"}). Two distinct approaches were used, rigid and flexible docking. After the rigid docking, the amino acid residues within 4.5 Å of the experimental ligand were chosen for flexible docking (Supplementary [Table](#t1){ref-type="table"} II). All docking simulations were carried out using AutoDock Vina software ([@B25]. The exhaustiveness was set to 8 to improve the docking search. Finally, DS Visualizer v.4.0 (Accelrys Software Inc, USA) was used to show the docking results of the binding conformations ([@B15].

Fig. 1: three-dimensional structure of the mammalian Ca2+-ATPase 1IWO (A) and parasite PfATP6 model (B).

TABLERigid and flexible binding energy (Kcal/mol) of molecular docking between *ent*-kaurane diterpenes (8, 9 and 21) and thapsigargin against PfATP6 and 1IWOCompounds1IWOPfATP6 1IWOPfATP6 Rigid Flexible8-7.6-7.7 -7.1-6.69-7.6-7.8 -6.6-6.321-9.5-8.4 -7.4-6.8Thapsigargin-7.7-7.2 -5.8-4.7

Fig. 2: interactions of thapsigargin (A) and *ent*-kaurane diterpene 21 (B) with the PfATP6 binding site.

A preliminary search indicated three main templates on PDB: 2O9J, 3BA6 and 1IWO, with 43%, 49% and 43.5% identity, respectively. All of them were used as a template to build the model ([Fig. 1](#f01){ref-type="fig"}) using Swiss Model Project Mode ([@B5], [@B19]).

Sequence alignment between PfATP6 and the templates showed a region with low similarity that was removed from PfATP6 to build the model. The PfATP6 refined model was evaluated based on the root-mean-square deviation (RMSD) value of the Cα coordinates and the Ramachandran Plot generated by PROCHECK software ([@B13]). Both methods compared against 1IWO showed an RMSD value of 1.61 Å and 87% of residues in the allowed regions; the corresponding percentage for the 1IWO crystal structure was 77.3%. This model is composed of three cytoplasmic domains, denoted as the actuator, phosphorylation and nucleotide binding domains; in addition, there are 10 transmembrane segments denoted as M1 to M10. Initially, the re-docking process showed the structural differences in the natural ligand before and after the molecular docking. The RMSD score was 1.12 Å, indicating that the structures of the molecules are similar to each other. The limit value accepted by the docking approach is 2.0 Å ([@B25]). As a result, AutoDock Vina software was used to generate the binding energies of diterpenes and the two enzymes.

The binding energies of the enzymes PfATP6 and 1IWO, as well as those of *ent*-kaurane diterpenes (8, 9 and 21) and TG are shown in [Table](#t1){ref-type="table"}. The three *ent-*kaurane diterpenes shown in [Table](#t1){ref-type="table"} were active against *P. falciparum* in vitro ([@B2]). Compound 21 was the most active, with a 50% inhibitory concentration (IC~50~) value of 5.4 µM. Compounds 8 and 9 displayed the highest selective antimalarial activity, with selective index values of 1,238.5 and 810.2, respectively. Compounds 8 and 9 exhibited similar binding energies to those of TG. Compound 21 showed the best docking results against PFATP6 and 1IWO, indicating a stronger interaction with the targets than that of TG, the natural inhibitor. [Fig. 2](#f02){ref-type="fig"} shows the interaction of TG and compound 21 with the PfATP6 binding site.

These data suggest PfATP6 as a potential target for the semisynthetic antimalarial diterpene epoxides derived from naturally occurring *ent-*kauranes from *W. paludosa*. The three *ent*-kaurane diterpenes presented similar binding energy values to those obtained with mammalian and parasite enzyme models. Further optimisation of these lead compounds may provide a more potent and selective antimalarial drug.
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###### Grid box size and position for both enzymes models

          Centre position             Box size                 
  ------- ----------------- --------- ---------- --- ---- ---- ----
  1IWO    -5.077            -47.902   8.882          28   26   30
  PfATP   -4.857            -24.528   7.832          26   32   28

###### Flexible amino acids of the active sites from the mammalian and parasite enzymes

  1IWO                  PfATP6                             
  --------------- ----- -------- --- --------------- ----- -----
  Leucine         LEU   253          Isoleucine      ILE   251
  Glutamate       GLU   255          Leucine         LEU   253
  Phenylalanine   PHE   256          Phenylalanine   PHE   254
  Glutamine       GLN   259          Glutamine       GLN   257
  Leucine         LEU   260          Leucine         LEU   258
  Valine          VAL   263          Isoleucine      ILE   261
  Isoleucine      ILE   761          Isoleucine      ILE   748
  Isoleucine      ILE   765          Isoleucine      ILE   752
  Aspartate       ASN   768          Aspartate       ASN   755
  Valine          VAL   769          Isoleucine      ILE   756
  Valine          VAL   772          Valine          VAL   759
  Valine          VAL   773          Phenylalanine   PHE   763
  Phenylalanine   PHE   776          Leucine         LEU   815
  Leucine         LEU   828          Isoleucine      ILE   816
  Isoleucine      ILE   829          Leucine         LEU   821
  Phenylalanine   PHE   834          Tyrosine        TYR   824
  Tyrosine        TYR   837          Isoleucine      ILE   825
  Methionine      MET   838          \-              \-    \-
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